Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-carnitine + N-acetyl cysteine is a combination antioxidant regimen consisting of levocarnitine and acetylcysteine. It has been investigated in a pilot clinical study by Ain Shams University for the treatment of male infertility, specifically targeting sperm DNA damage in adult males with beta thalassemia major (BTM). In BTM, iron overload leads to the excessive formation of reactive oxygen species (ROS), which causes oxidative stress and subsequent damage to the hypothalamic-pituitary-testicular axis and sperm DNA. This combination therapy aims to reduce the DNA fragmentation index and improve sperm morphology by scavenging ROS and neutralizing free radicals. The treatment is typically administered orally over a six-month period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levocarnitine + acetylcysteine (Ain Shams University).